A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection
Latest Information Update: 30 May 2025
At a glance
- Drugs CRS 3123 (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- Sponsors Crestone
Most Recent Events
- 25 May 2025 Status changed from active, no longer recruiting to completed.
- 05 Sep 2024 Positive topline results evaluating CRS3123 in patients with Clostridioides difficile infection (CDI) , published in the Crestone Media Release
- 20 Feb 2024 Status changed from recruiting to active, no longer recruiting.